Summary

Rheumatology Therapeutics Market – Scope of Report
TMR’s report on the global rheumatology therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global rheumatology therapeutics market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global rheumatology therapeutics market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the rheumatology therapeutics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global rheumatology therapeutics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global rheumatology therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global rheumatology therapeutics market.

The report delves into the competitive landscape of the global rheumatology therapeutics market. Key players operating in the global rheumatology therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global rheumatology therapeutics market profiled in this report.

Key Questions Answered in Global rheumatology therapeutics Market Report
• What is the sales/revenue generated by rheumatology therapeutics across all regions during the forecast period?
• What are the opportunities in the global rheumatology therapeutics market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Rheumatology Therapeutics Market – Research Objectives and Research Approach
The comprehensive report on the global rheumatology therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global rheumatology therapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global rheumatology therapeutics market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Rheumatology Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Rheumatology Therapeutics Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Rheumatology Therapeutics Market Analysis and Forecast, by Drug Class
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Class, 2020-2034
6.3.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
6.3.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
6.3.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
6.3.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
6.3.3. Corticosteroids
6.3.4. Uric Acid Drugs
6.3.5. Others
6.4. Market Attractiveness, by Drug Class
7. Global Rheumatology Therapeutics Market Analysis and Forecast, by Disease Indication
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Disease Indication, 2020-2034
7.3.1. Rheumatoid Arthritis
7.3.2. Osteoarthritis
7.3.3. Gout
7.3.4. Psoriatic Arthritis
7.3.5. Ankylosing Spondylitis
7.3.6. Others
7.4. Market Attractiveness, by Disease Indication
8. Global Rheumatology Therapeutics Market Analysis and Forecast, by Route of Administration
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Route of Administration, 2020-2034
8.3.1. Parenteral Route
8.3.2. Oral Route
8.3.3. Topical
8.4. Market Attractiveness, by Route of Administration
9. Global Rheumatology Therapeutics Market Analysis and Forecast, by Distribution Channel
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Distribution Channel, 2020-2034
9.3.1. Hospital Pharmacy
9.3.2. Retail Pharmacy
9.3.3. Online Pharmacy
9.4. Market Attractiveness, by Distribution Channel
10. Global Rheumatology Therapeutics Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2020-2034
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Region
11. North America Rheumatology Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Class, 2020-2034
11.2.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
11.2.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
11.2.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
11.2.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
11.2.3. Corticosteroids
11.2.4. Uric Acid Drugs
11.2.5. Others
11.3. Market Attractiveness, by Drug Class
11.4. Market Value Forecast, by Disease Indication, 2020-2034
11.4.1. Rheumatoid Arthritis
11.4.2. Osteoarthritis
11.4.3. Gout
11.4.4. Psoriatic Arthritis
11.4.5. Ankylosing Spondylitis
11.4.6. Others
11.5. Market Attractiveness, by Disease Indication
11.6. Market Value Forecast, by Route of Administration, 2020-2034
11.6.1. Parenteral Route
11.6.2. Oral Route
11.6.3. Topical
11.7. Market Attractiveness, by Route of Administration
11.8. Market Value Forecast, by Distribution Channel, 2020-2034
11.8.1. Hospital Pharmacy
11.8.2. Retail Pharmacy
11.8.3. Online Pharmacy
11.9. Market Attractiveness, by Distribution Channel
11.10. Market Value Forecast, by Country/Sub-region, 2020-2034
11.10.1. U.S.
11.10.2. Canada
11.11. Market Attractiveness Analysis
11.11.1. By Drug Class
11.11.2. By Disease Indication
11.11.3. By Route of Administration
11.11.4. By Distribution Channel
11.11.5. By Country
12. Europe Rheumatology Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2020-2034
12.2.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
12.2.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
12.2.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
12.2.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
12.2.3. Corticosteroids
12.2.4. Uric Acid Drugs
12.2.5. Others
12.3. Market Attractiveness, by Drug Class
12.4. Market Value Forecast, by Disease Indication, 2020-2034
12.4.1. Rheumatoid Arthritis
12.4.2. Osteoarthritis
12.4.3. Gout
12.4.4. Psoriatic Arthritis
12.4.5. Ankylosing Spondylitis
12.4.6. Others
12.5. Market Attractiveness, by Disease Indication
12.6. Market Value Forecast, by Route of Administration, 2020-2034
12.6.1. Parenteral Route
12.6.2. Oral Route
12.6.3. Topical
12.7. Market Attractiveness, by Route of Administration
12.8. Market Value Forecast, by Distribution Channel, 2020-2034
12.8.1. Hospital Pharmacy
12.8.2. Retail Pharmacy
12.8.3. Online Pharmacy
12.9. Market Attractiveness, by Distribution Channel
12.10. Market Value Forecast, by Country/Sub-region, 2020-2034
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Market Attractiveness Analysis
12.11.1. By Drug Class
12.11.2. By Disease Indication
12.11.3. By Route of Administration
12.11.4. By Distribution Channel
12.11.5. By Country/Sub-region
13. Asia Pacific Rheumatology Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Class, 2020-2034
13.2.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
13.2.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
13.2.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
13.2.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
13.2.3. Corticosteroids
13.2.4. Uric Acid Drugs
13.2.5. Others
13.3. Market Attractiveness, by Drug Class
13.4. Market Value Forecast, by Disease Indication, 2020-2034
13.4.1. Rheumatoid Arthritis
13.4.2. Osteoarthritis
13.4.3. Gout
13.4.4. Psoriatic Arthritis
13.4.5. Ankylosing Spondylitis
13.4.6. Others
13.5. Market Attractiveness, by Disease Indication
13.6. Market Value Forecast, by Route of Administration, 2020-2034
13.6.1. Parenteral Route
13.6.2. Oral Route
13.6.3. Topical
13.7. Market Attractiveness, by Route of Administration
13.8. Market Value Forecast, by Distribution Channel, 2020-2034
13.8.1. Hospital Pharmacy
13.8.2. Retail Pharmacy
13.8.3. Online Pharmacy
13.9. Market Attractiveness, by Distribution Channel
13.10. Market Value Forecast, by Country/Sub-region, 2020-2034
13.10.1. China
13.10.2. Japan
13.10.3. India
13.10.4. Australia & New Zealand
13.10.5. Rest of Asia Pacific
13.11. Market Attractiveness Analysis
13.11.1. By Drug Class
13.11.2. By Disease Indication
13.11.3. By Route of Administration
13.11.4. By Distribution Channel
13.11.5. By Country/Sub-region
14. Latin America Rheumatology Therapeutics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Class, 2020-2034
14.2.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
14.2.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
14.2.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
14.2.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
14.2.3. Corticosteroids
14.2.4. Uric Acid Drugs
14.2.5. Others
14.3. Market Attractiveness, by Drug Class
14.4. Market Value Forecast, by Disease Indication, 2020-2034
14.4.1. Rheumatoid Arthritis
14.4.2. Osteoarthritis
14.4.3. Gout
14.4.4. Psoriatic Arthritis
14.4.5. Ankylosing Spondylitis
14.4.6. Others
14.5. Market Attractiveness, by Disease Indication
14.6. Market Value Forecast, by Route of Administration, 2020-2034
14.6.1. Parenteral Route
14.6.2. Oral Route
14.6.3. Topical
14.7. Market Attractiveness, by Route of Administration
14.8. Market Value Forecast, by Distribution Channel, 2020-2034
14.8.1. Hospital Pharmacy
14.8.2. Retail Pharmacy
14.8.3. Online Pharmacy
14.9. Market Attractiveness, by Distribution Channel
14.10. Market Value Forecast, by Country/Sub-region, 2020-2034
14.10.1. Brazil
14.10.2. Mexico
14.10.3. Rest of Latin America
14.11. Market Attractiveness Analysis
14.11.1. By Drug Class
14.11.2. By Disease Indication
14.11.3. By Route of Administration
14.11.4. By Distribution Channel
14.11.5. By Country/Sub-region
15. Middle East & Africa Rheumatology Therapeutics Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Drug Class, 2020-2034
15.2.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
15.2.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
15.2.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
15.2.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
15.2.3. Corticosteroids
15.2.4. Uric Acid Drugs
15.2.5. Others
15.3. Market Attractiveness, by Drug Class
15.4. Market Value Forecast, by Disease Indication, 2020-2034
15.4.1. Rheumatoid Arthritis
15.4.2. Osteoarthritis
15.4.3. Gout
15.4.4. Psoriatic Arthritis
15.4.5. Ankylosing Spondylitis
15.4.6. Others
15.5. Market Attractiveness, by Disease Indication
15.6. Market Value Forecast, by Route of Administration, 2020-2034
15.6.1. Parenteral Route
15.6.2. Oral Route
15.6.3. Topical
15.7. Market Attractiveness, by Route of Administration
15.8. Market Value Forecast, by Distribution Channel, 2020-2034
15.8.1. Hospital Pharmacy
15.8.2. Retail Pharmacy
15.8.3. Online Pharmacy
15.9. Market Attractiveness, by Distribution Channel
15.10. Market Value Forecast, by Country/Sub-region, 2020-2034
15.10.1. GCC Countries
15.10.2. South Africa
15.10.3. Rest of Middle East & Africa
15.11. Market Attractiveness Analysis
15.11.1. By Drug Class
15.11.2. By Disease Indication
15.11.3. By Route of Administration
15.11.4. By Distribution Channel
15.11.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2023)
16.3. Company Profiles
16.3.1. F. Hoffmann-La Roche Ltd.
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. AbbVie, Inc.
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. Pfizer, Inc.
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Takeda Pharmaceutical Company Limited
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Amgen, Inc.
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. Genentech, Inc.
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Novartis AG
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Johnson & Johnson Innovative Medicine
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Sanofi
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. Merck & Co., Inc.
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. Financial Overview
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview